PL1991201T3 - Nebulizowane antybiotyki do terapii inhalacyjnej - Google Patents

Nebulizowane antybiotyki do terapii inhalacyjnej

Info

Publication number
PL1991201T3
PL1991201T3 PL07703355T PL07703355T PL1991201T3 PL 1991201 T3 PL1991201 T3 PL 1991201T3 PL 07703355 T PL07703355 T PL 07703355T PL 07703355 T PL07703355 T PL 07703355T PL 1991201 T3 PL1991201 T3 PL 1991201T3
Authority
PL
Poland
Prior art keywords
nebulised
antibiotics
inhalation therapy
inhalation
therapy
Prior art date
Application number
PL07703355T
Other languages
English (en)
Inventor
Manfred Keller
Aslihan Akkar
Original Assignee
Pari Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pari Pharma Gmbh filed Critical Pari Pharma Gmbh
Publication of PL1991201T3 publication Critical patent/PL1991201T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07703355T 2006-02-10 2007-02-08 Nebulizowane antybiotyki do terapii inhalacyjnej PL1991201T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06002734 2006-02-10
PCT/EP2007/001080 WO2007090646A1 (en) 2006-02-10 2007-02-08 Nebulised antibiotics for inhalation therapy
EP07703355.3A EP1991201B1 (en) 2006-02-10 2007-02-08 Nebulised antibiotics for inhalation therapy

Publications (1)

Publication Number Publication Date
PL1991201T3 true PL1991201T3 (pl) 2018-09-28

Family

ID=36607472

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07703355T PL1991201T3 (pl) 2006-02-10 2007-02-08 Nebulizowane antybiotyki do terapii inhalacyjnej

Country Status (19)

Country Link
US (1) US20090025713A1 (pl)
EP (1) EP1991201B1 (pl)
JP (1) JP2009526003A (pl)
CN (1) CN101389313A (pl)
AU (1) AU2007213983B2 (pl)
BR (1) BRPI0707641A2 (pl)
CA (1) CA2641827A1 (pl)
CY (1) CY1120284T1 (pl)
DK (1) DK1991201T3 (pl)
ES (1) ES2671342T3 (pl)
HU (1) HUE037773T2 (pl)
LT (1) LT1991201T (pl)
MX (1) MX2008010222A (pl)
PL (1) PL1991201T3 (pl)
PT (1) PT1991201T (pl)
RU (1) RU2008136460A (pl)
SI (1) SI1991201T1 (pl)
TR (1) TR201807714T4 (pl)
WO (1) WO2007090646A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545463B2 (en) * 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
CA2526362C (en) * 2003-05-20 2012-10-09 James F. Collins Ophthalmic drug delivery system
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0602980D0 (en) * 2006-02-14 2006-03-29 Optinose As Delivery device and method
EP2030644A1 (en) * 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
US8551534B2 (en) 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
US20090212133A1 (en) * 2008-01-25 2009-08-27 Collins Jr James F Ophthalmic fluid delivery device and method of operation
CA2716936C (en) * 2008-02-26 2018-06-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CA2739893C (en) * 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
KR101959873B1 (ko) 2008-10-07 2019-03-19 랩터 파마슈티컬스 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
US8168597B2 (en) 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
JP5960434B2 (ja) * 2009-02-18 2016-08-02 アラダイム コーポレーション 肺送達のためのpH調節された製剤
PL2248517T3 (pl) * 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
JP2013502416A (ja) * 2009-08-19 2013-01-24 エムペックス ファーマスーティカルズ,インコーポレイテッド 慢性閉塞性肺疾患治療用のエアロゾル化された抗生物の使用
WO2011029059A1 (en) * 2009-09-04 2011-03-10 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
AU2015275224C1 (en) * 2009-09-04 2017-11-16 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
KR20130043611A (ko) * 2010-02-25 2013-04-30 다이이찌 산쿄 가부시키가이샤 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도
KR102012418B1 (ko) * 2010-07-12 2019-08-20 셀리아 파마슈티칼즈 에이피에스 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
JP2013531548A (ja) 2010-07-15 2013-08-08 コリンシアン オフサルミック,インコーポレイティド 遠隔治療及び遠隔モニタリングを実施する方法及びシステム
AU2011278934B2 (en) 2010-07-15 2015-02-26 Eyenovia, Inc. Drop generating device
EP2485691B1 (en) 2010-07-15 2020-03-18 Eyenovia, Inc. Ophthalmic drug delivery
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
JP6105621B2 (ja) 2011-12-12 2017-03-29 アイノビア,インコーポレイティド 高弾性高分子エジェクタ機構、エジェクタ装置及びそれらの使用方法
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US10064583B2 (en) 2013-08-07 2018-09-04 Covidien Lp Detection of expiratory airflow limitation in ventilated patient
WO2015066282A1 (en) * 2013-10-30 2015-05-07 Inspirx Llc Inhaled aerosolized immuno-chemotherapy for the treatment of mdr tb
PL3104853T3 (pl) * 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
ES2792682T3 (es) 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
US10518288B2 (en) 2015-06-10 2019-12-31 Stamford Devices Limited Aerosol generation
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
CA3024522C (en) 2016-05-31 2024-06-25 Polyphor Ag Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
AU2017298202A1 (en) * 2016-07-16 2019-02-07 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CN107669636A (zh) * 2016-09-30 2018-02-09 青岛大学 一种氨溴索喷雾剂
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア,インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
CN109419785A (zh) * 2017-08-31 2019-03-05 正大青春宝药业有限公司 一种鱼腥草提取物制剂及其应用
IT201900006104A1 (it) * 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Metodo di preparazione di un prodotto a base di chitosano
CN112569211A (zh) * 2019-09-27 2021-03-30 盈科瑞(天津)创新医药研究有限公司 一种吸入用加替沙星溶液及其制备方法
US12161585B2 (en) 2019-12-11 2024-12-10 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN114948914B (zh) * 2022-06-30 2024-04-02 北京新领先医药科技发展有限公司 一种盐酸莫西沙星雾化吸入用溶液剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0868183B1 (en) * 1995-12-21 2002-01-30 Pfizer Inc. Injectable quinolone formulations
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
ES2234266T3 (es) * 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
US6070575A (en) * 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6397838B1 (en) * 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US6550472B2 (en) * 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
ES2473591T3 (es) * 2001-07-31 2014-07-07 Philip Morris Products S.A. Método y aparato para generar líquidos volatilizados
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
US6702997B2 (en) * 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ, インク. 細胞内感染を予防及び治療するための吸入システム
DE10239321B3 (de) * 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
EP1628637A2 (en) * 2003-05-30 2006-03-01 Alza Corporation Method of pulmonary administration of an agent
WO2005048982A2 (en) * 2003-11-17 2005-06-02 Nektar Therapeutics Efficient introduction of an aerosol into a ventilator circuit
AU2004311478A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP2008500965A (ja) * 2004-03-17 2008-01-17 エムペックス・ファーマシューティカルズ・インコーポレーテッド 細菌の排出ポンプ阻害剤の使用および投与
EP2594272B1 (en) * 2005-05-18 2018-07-11 Horizon Orphan LLC Aerosolized fluoroquinolones and uses thereof

Also Published As

Publication number Publication date
CA2641827A1 (en) 2007-08-16
AU2007213983A1 (en) 2007-08-16
ES2671342T3 (es) 2018-06-06
MX2008010222A (es) 2008-10-17
CY1120284T1 (el) 2019-07-10
WO2007090646A1 (en) 2007-08-16
DK1991201T3 (en) 2018-06-14
TR201807714T4 (tr) 2018-06-21
SI1991201T1 (en) 2018-08-31
JP2009526003A (ja) 2009-07-16
AU2007213983B2 (en) 2012-09-20
EP1991201A1 (en) 2008-11-19
CN101389313A (zh) 2009-03-18
RU2008136460A (ru) 2010-03-20
PT1991201T (pt) 2018-06-12
BRPI0707641A2 (pt) 2011-05-10
HUE037773T2 (hu) 2018-09-28
LT1991201T (lt) 2018-07-25
EP1991201B1 (en) 2018-03-28
US20090025713A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
LT1991201T (lt) Puškiami antibiotikai inhaliaciniam gydymui
IL197316A0 (en) Buprenophine-wafer for drug substitution therapy
EP2101855A4 (en) ADMINISTRATION OF ANTI-THERAPY
IL196702A0 (en) Trauma therapy
PT1973598T (pt) Método e dispositivo para terapia farmacológica ativada por luz
IL195247A0 (en) Inhaler
HUE038232T2 (hu) Inhalátor
IL236360A0 (en) Inhalable medicine
GB2434754B (en) Inhaler
ZA200806929B (en) Nebulizer formulation
IL197125A0 (en) Drug combinations for treating airway diseases
EP2123295A4 (en) THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA
AP2006000208S (en) Inhaler
AU311491S (en) Inhaler
PH32006000029S1 (en) Atomizer for inhaler
GB2437806B (en) Novel therapeutic delivery system
GB0524945D0 (en) Medicament inhaler
PH32006000910S1 (en) Inhaler
GB0612693D0 (en) Inhaler
PH32006000028S1 (en) Inhaler
PH32006000619S1 (en) Inhaler
GB0613459D0 (en) Novel therapeutic delivery system
GB0608669D0 (en) Novel Therapeutic Delivery System
GB0615039D0 (en) Therapy
GB0616871D0 (en) Therapy